The Movement Disorder Society (MDS) International Congress 2026 represents a critical venue for advancing Huntington's disease (HD) research and clinical care. Held in Seoul, Korea, MDS 2026 will feature dedicated sessions addressing the latest advances in understanding, treating, and ultimately preventing this devastating neurodegenerative disorder[1].
Huntington's disease is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, which encodes the huntingtin protein. The mutation leads to progressive degeneration of striatal and cortical neurons, manifesting as a triad of motor, cognitive, and psychiatric symptoms that inexorably worsen over 15-25 years[2].
The MDS 2026 congress, with its theme of "Understanding Aging in Movement Disorders," provides a particularly relevant context for HD research, given the interplay between the aging process and disease progression. The Congress will feature:
| Item | Details |
|---|---|
| Dates | October 4-8, 2026 |
| Location | Seoul, Korea — COEX Convention and Exhibition Center |
| Organizer | Movement Disorder Society |
| Website | www.mdscongress.org |
| Theme | Understanding Aging in Movement Disorders |
The field of HD gene therapy has made remarkable progress, with multiple modalities advancing toward clinical application:
Novel CRISPR/CasRx approaches have demonstrated significant reduction of HTT mRNA levels in HD models. These RNA-targeting systems offer advantages over DNA-editing approaches:
ASOs remain the most advanced gene-silencing approach in clinical development:
Tominersen (RG6042)
Other ASO Programs
Zinc Finger Nucleases (ZFNs)
CRISPR-Cas9 Base Editing
Prime Editing
Multiple approaches aim to slow or halt HD progression:
Aggregation Modulators
HTT Post-Translational Modification Modulators
Mitochondrial Protectants
Excitotoxicity Blockers
Anti-Inflammatory Approaches
Stem Cell Approaches
The halted trials of 2021 provided critical insights:
Key Learnings
New Trial Designs
Fluid Biomarkers
Imaging Biomarkers
Digital Biomarkers
Long-term observational studies are informing clinical trial design:
Chorea Treatments
Non-Chorea Motor Symptoms
Mood Disorders
Cognitive Dysfunction
Psychiatric Symptoms
The pathological aggregation of mutant huntingtin protein represents a central therapeutic target:
The CAG repeat tract shows dynamic behavior influencing disease:
Mutant huntingtin disrupts normal gene expression patterns:
Energy metabolism impairment is a key disease mechanism:
Multiple approaches to enhance mutant huntingtin clearance:
The contribution of neuroinflammation to disease progression:
Early deficits in synaptic function:
Enhancing cellular clearance:
Bates GP, et al. Huntington's disease. Nat Rev Dis Primers. 2015. 2015. ↩︎
Rossi S, et al. RNA-Targeting CRISPR/CasRx for Huntington's disease. Mol Neurodegener. 2025. 2025. ↩︎
Leavitt BR, et al. Huntingtin-lowering therapies for Huntington's disease. Nat Rev Neurol. 2020. 2020. ↩︎
Mendel JR, et al. Antisense oligonucleotide therapy for Huntington's disease: Current status and future directions. Nat Rev Neurol. 2023. 2023. ↩︎
Roach AH, et al. Zinc finger nucleases for allele-selective huntingtin lowering in Huntington's disease. Nat Med. 2024. 2024. ↩︎
Kim H, et al. Base editing for Huntington's disease: Precision gene therapy approaches. Nat Biotechnol. 2024. 2024. ↩︎
Hughes CA, et al. Mitochondrial dysfunction in Huntington's disease: From mechanisms to therapeutics. Brain. 2024. 2024. ↩︎ ↩︎
Stringer J, et al. Neuroinflammation in Huntington's disease: Pathogenesis and therapeutic targeting. Nat Rev Neurosci. 2023. 2023. ↩︎
Gonzalez RF, et al. Cell-based therapies for Huntington's disease: Current status and future directions. Brain. 2024. 2024. ↩︎
Landles C, et al. Huntington's disease: Expanding therapeutics beyond mutant huntingtin. Nat Rev Neurol. 2020. 2020. ↩︎
Fischer R, et al. Huntington's disease biomarkers: Current status and future perspectives. Nat Rev Neurol. 2022. 2022. ↩︎
Schultz JL, et al. Digital biomarkers in Huntington's disease: Applications for clinical trials and monitoring. Nat Rev Neurol. 2022. 2022. ↩︎
McGowan A, et al. Deutetrabenazine for chorea in Huntington's disease: Efficacy and safety. Mov Disord. 2023. 2023. ↩︎
Wheelock VL, et al. Valbenazine for the treatment of chorea in Huntington's disease. Mov Disord. 2023. 2023. ↩︎
Kumar P, et al. Neuropsychiatric symptoms in Huntington's disease: From pathophysiology to management. Lancet Psychiatry. 2024. 2024. ↩︎
Day SE, et al. CAG repeat instability in Huntington's disease: Mechanisms and therapeutic implications. Nat Rev Neurol. 2023. 2023. ↩︎
Schulte J, et al. Transcriptional dysregulation in Huntington's disease: Molecular mechanisms and therapeutic approaches. Nat Rev Neurosci. 2024. 2024. ↩︎